Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents

摘要

A method of treating a human being suffering from an hormone-dependent disorder characterized by the overexpression of HER2 comprising administering to said human being an aromatase inhibitor e.g. exemestane, fadrozole, letrozole and anastrozole and an antibody against HER2 e.g. trastuzumab, in amounts effective to produce a superadditive or synergistic therapeutic effect.